23andMe sees independent board directors quit en masse

23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink. Fading interest in DNA kits – 23andMe’s main product –  was one driver. So was news last year that hackers stole ancestry data on 6.9 […]
© 2024 TechCrunch. All rights reserved. For personal use only.
Source: TECCRUCH

リンク元